What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 5

The recent 42% drawdown is viewed as a major buying opportunity, disconnected from strong performance. The new lab testing service is a massive potential growth driver, and the valuation is described as an 'absolute steal'.

Strategically positioning itself as a key distribution platform for the mass adoption of GLP-1 weight-loss drugs, which is viewed as a massive growth opportunity.

The speaker is extremely bullish, citing a major new product with a 300 million person TAM that aims to disrupt primary care, which the market is ignoring.

Cited as an example of a hyper-growth small-cap stock that is currently weak due to the broader market liquidity crisis affecting risky assets.

The stock's 34% decline is seen as a disconnect from strong Q3 performance. Potential catalysts include a renewed partnership with Novo Nordisk for GLP-1 drugs, new product lines for testosterone and menopause, and a 'big announcement' scheduled for November 13th.

Serves as the main industry comparable and valuation benchmark for LifeMD. The significant valuation gap between HIMS and LFMD is the core of the bullish thesis for LFMD, as Hims trades at a much higher valuation multiple.

The recent stock drop is seen as a significant buying opportunity, as it is attributed to a market-wide sell-off and is disconnected from the company's 'amazing' Q3 earnings (49% YoY revenue growth). Future catalysts include a new product reveal and potential partnerships.

The company is considered undervalued and 'very, very cheap' with outstanding Q3 results showing a strong revenue growth rebound, increasing profitability, and impressive customer metrics. The analysis suggests the stock should be valued more like a high-growth SaaS company.

The speaker is very bullish long-term, viewing the $4.00 - $4.50 price range as a cheap entry point, with key growth drivers in microdose GLP-1s, testosterone, and menopause treatments.

Mentioned as an example of a strong company whose stock was 'dumping' for no clear reason, reinforcing the view that the market is currently fearful and irrational.

Viewed as a long-term growth investment disrupting the healthcare industry. New product lines like Testosterone and Menopause treatments are expected to be huge growth drivers. Recent dips are viewed as buying opportunities.

Making a strategic long-term investment in Grail for cancer screening, positioning it as a future leader in preventative care. The stock is currently volatile and down, which the speaker views as a buying opportunity.

Described as a stock that 'trades on sentiment' more than others and is expected to be very volatile, going 'back up' and then 'back down'.

The stock was 'wrecked,' falling 16% in a single day due to negative sentiment related to the GLP-1 drug space, indicating high risk and uncertainty.

The speaker views the 21% drop in the stock price as a 'buying opportunity' based on a market overreaction, arguing that HIMS is a diversified telehealth platform and not just a GLP-1 company.

Considered very bearish due to multiple red flags: questionable insider selling by the CEO, a 'sell' rating from Bank of America, and ongoing legal/regulatory risks.

The recent 7% drop is viewed as a buying opportunity, as the market is believed to be ignoring major positive news (expansion into menopause treatment) and the company's strong growth fundamentals.

The expansion into the menopause market is seen as a significant growth driver. The host believes the company is cheap with strong growth rates, though he sold half his position for portfolio management after a large run-up.

The launch of its Menopause product line is considered a major growth catalyst, opening up an enormous and underserved addressable market. The 'Hers' business segment is projected to reach $1 billion in sales by 2026.

Considered 'too cheap' after an irrational sell-off, presenting a buying opportunity ahead of bullish catalysts like new product lines (testosterone, menopause) and international expansion. Attractive entry points are cited at $51-$53.

The speaker is bullish, viewing the nearly 10% drop as a buying opportunity. The sell-off is considered illogical as the company has a defensive subscription model and high margins, and was likely sold off due to being a small-cap stock in a market panic.

The stock was down almost 8% and is viewed as a 'buy the dip' opportunity, as its sell-off is attributed to irrational market panic ('basket selling') rather than any weakness in the business.

While included in the MEME ETF, the host believes it to be a 'legitimate growth company,' not a meme stock, implying a positive fundamental view.

The market is seen as misunderstanding the company as just a weight-loss drug seller, while it is a disruptive digital health platform with a 'still very cheap' stock and multiple growth catalysts like expansion into testosterone and menopause treatments.

The stock was down significantly, attributed to a potential 'hit piece' and news that the founder was stepping down.

The speaker is extremely bullish, viewing the recent price drop as a 'buy the dip opportunity' because the market misunderstands its integrated business model, which creates a strong competitive moat through bundled services and customization.

Mentioned as a 'channel favorite' where recent extreme intraday volatility (dropping 5% at the open before closing positive) is viewed as a potential buying opportunity.

The speaker expressed a clear intention to stay away from this stock, stating there is 'no reason to trade that thing,' indicating a bearish or avoidant stance.

Focusing on high-demand, lifestyle-oriented healthcare markets (weight loss, hair loss, sexual health, mental health) through its direct-to-consumer telehealth platform.

The speaker's proprietary trading tool suggested a short position on the stock, which he also called 'tough'.

The stock rallied 16% in two days, serving as another case study that investors need to hold positions to benefit from sudden, unpredictable price increases.

The stock's positive performance is attributed to the market positively 'digesting the news of the testosterone launch,' which is viewed as a significant and bullish catalyst for future growth.

The launch of TRT and at-home lab testing is a significant growth catalyst. The stock is considered undervalued ('super cheap') and 'highest quality in its sector', making it an attractive long-term investment despite high volatility.

Directly criticized by competitor Mark Cuban, who stated customers are 'getting ripped off,' highlighting significant competitive pressure from low-cost alternatives which could threaten its pricing power and margins.

Shows explosive growth and incredible stock performance, but its weak moat and operation in a high-risk industry (pharmaceuticals) warrant caution for long-term investors.

The investment thesis is strengthening as GLP-1 lawsuit risks fade and the company pivots to a new HRT market. The business has high recurring revenue, is cash-pay, and recession-resistant.

High volatility and short squeeze potential due to 35% short interest. Legal risks concerning GLP-1s may be overstated. A rumored testosterone product launch is a significant upcoming catalyst.

The stock rallied after a judge dismissed a lawsuit against a compounding pharmacy, which is viewed as a positive legal precedent for its business model.

The speaker is very bullish, viewing the high 34% short interest as a major miscalculation by Wall Street, creating a potential for a short squeeze. Catalysts include new treatments, international expansion, and a future generic semaglutide launch.

The company's business model targets large and expanding wellness markets (weight loss, mental health) through a convenient digital platform, which could be a significant growth driver.

A key player in the parallel market for weight loss drugs, representing a high-risk, high-reward opportunity. The company's future depends on its ability to navigate significant legal and regulatory challenges as its business model, built on a now-ended drug shortage, is in a 'regulatory gray area'.

The market is incorrectly viewing HIMS as only a GLP-1 company, while it is a diversified, disruptive telehealth platform with multiple growth catalysts, including new treatments (menopause, testosterone) and international expansion. The recent sell-off is seen as a buying opportunity.

Considered a 'steal' at $42, as the market is overly focused on perceived GLP-1 lawsuit risk while ignoring its diversified business model.

Faces a significant competitive threat from Novo Nordisk's Ozempic price cut, received a downgrade from Truist (price target lowered to $37), and the CEO has been selling shares.

Presented as a current bearish idea based on a combination of weakening business fundamentals (negative press, slowing growth) and a strong insider sell signal (a massive sale by the CEO).

Multiple insiders, including the CEO, made large, unscheduled sales totaling almost $40 million, which is a significant red flag suggesting a lack of confidence and potential for more negative news.

Mentioned as a past successful investment for the host and used as a valuation comparable, with the host noting it has a similarly 'cheap' valuation to KULR.

Sentiment is mixed to cautiously bearish due to a significant 'lawsuit overhang' from Novo Nordisk over its practice of selling compounded semaglutide. While the market leader, its growth has been revised down, and the end of a partnership with Novo Nordisk is expected to create a 'dent in the quarterly revenue'.

The CEO sold over $30 million worth of stock, which is considered a noteworthy bearish signal, suggesting the insider may see the current price as high or anticipate headwinds.

The CEO made his largest-ever, unscheduled sale of $5 million after a 200% stock run-up. This is a strong bearish signal suggesting he believes the stock is overvalued.